The HIV-1 protease as a therapeutic target for AIDS
- PMID: 1540403
- DOI: 10.1089/aid.1992.8.153
The HIV-1 protease as a therapeutic target for AIDS
Abstract
HIV produces a small , dimeric aspartyl protease which specifically cleaves the polyprotein precursors encoding the structural proteins and enzymes of the virus. This proteolytic activity is absolutely required for the production of mature, infectious virions and is therefore an attractive target for therapeutic intervention. This review summarizes the strategies and multidisciplinary efforts that have been applied to date to the identification of specific inhibitors of this critical viral enzyme. These inhibitors include rationally designed peptide substrate analogs, compounds conceived from tertiary structure information on the enzyme and natural products. Future directions in the discovery and development of HIV-1 protease inhibitors are also discussed.
Similar articles
-
Inhibitors of HIV-1 protease.J Enzyme Inhib. 1992;6(1):65-98. doi: 10.3109/14756369209041357. J Enzyme Inhib. 1992. PMID: 1285304 Review.
-
HIV protease: a novel chemotherapeutic target for AIDS.J Med Chem. 1991 Aug;34(8):2305-14. doi: 10.1021/jm00112a001. J Med Chem. 1991. PMID: 1875332 Review. No abstract available.
-
HIV-1 protease as a potential target for anti-AIDS therapy.Ann N Y Acad Sci. 1990;616:41-53. doi: 10.1111/j.1749-6632.1990.tb17826.x. Ann N Y Acad Sci. 1990. PMID: 2078031 Review. No abstract available.
-
Structural mechanisms of HIV drug resistance.Annu Rev Pharmacol Toxicol. 1996;36:545-71. doi: 10.1146/annurev.pa.36.040196.002553. Annu Rev Pharmacol Toxicol. 1996. PMID: 8725401 Review.
-
Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.Acc Chem Res. 2008 Oct;41(10):1252-63. doi: 10.1021/ar8000519. Epub 2008 Aug 6. Acc Chem Res. 2008. PMID: 18681464
Cited by
-
Substitution Models of Protein Evolution with Selection on Enzymatic Activity.Mol Biol Evol. 2024 Feb 1;41(2):msae026. doi: 10.1093/molbev/msae026. Mol Biol Evol. 2024. PMID: 38314876 Free PMC article.
-
In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.J Clin Microbiol. 2001 Mar;39(3):1124-9. doi: 10.1128/JCM.39.3.1124-1129.2001. J Clin Microbiol. 2001. PMID: 11230439 Free PMC article.
-
AIDS: The final chapter?AIDS Res Hum Retroviruses. 2014 Jan;30(1):5-7. doi: 10.1089/aid.2013.1503. AIDS Res Hum Retroviruses. 2014. PMID: 24392796 Free PMC article. No abstract available.
-
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.Clin Pharmacokinet. 1997 Mar;32(3):194-209. doi: 10.2165/00003088-199732030-00003. Clin Pharmacokinet. 1997. PMID: 9084959 Review.
-
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.Antimicrob Agents Chemother. 1997 May;41(5):965-71. doi: 10.1128/AAC.41.5.965. Antimicrob Agents Chemother. 1997. PMID: 9145853 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical